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Gaucher disease results from the inherited deﬁciency of the enzyme glucocerebrosidase (EC 3.2.1.45). Although
1100 mutations in the gene for human glucocerebrosidase have been described, most genotype-phenotype studies
have focused upon screening for a few common mutations. In this study, we used several approaches—including
direct sequencing, Southern blotting, long-template PCR, restriction digestions, and the ampliﬁcation refraction
mutation system (ARMS)—to genotype 128 patients with type 1 Gaucher disease (64 of Ashkenazi Jewish ancestry
and 64 of non-Jewish extraction) and 24 patients with type 3 Gaucher disease. More than 97% of the mutant
alleles were identiﬁed. Fourteen novel mutations (A90T, N117D, T134I, Y135X, R170C, W184R, A190T, Y304X,
A341T, D399Y, c.153-154insTACAGC, c.203-204insC, c.222-224delTAC, and c.1122-1123insTG) and many rare
mutations were detected. Recombinant alleles were found in 19% of the patients. Although 93% of the mutant
alleles in our Ashkenazi Jewish type 1 patients were N370S, c.84-85insG, IVS2+1GrA or L444P, these four
mutations accounted for only 49% of mutant alleles in the non-Jewish type 1 patients. Genotype-phenotype cor-
relations were attempted. Homozygosity or heterozygosity for N370S resulted in type 1 Gaucher disease, whereas
homozygosity for L444P was associated with type 3. Genotype L444P/recombinant allele resulted in type 2 Gaucher
disease, and homozygosity for a recombinant allele was associated with perinatal lethal disease. The phenotypic
consequences of other mutations, particularly R463C, were more inconsistent. Our results demonstrate a high rate
of mutation detection, a large number of novel and rare mutations, and an accurate assessment of the prevalence
of recombinant alleles. Although some genotype-phenotype correlations do exist, other genetic and environmental
factors must also contribute to the phenotypes encountered, and we caution against relying solely upon genotype
for prognostic or therapeutic judgements.
Introduction
Gaucher disease (MIM 230800), the most common gly-
colipid storage disorder, results from the inherited de-
ﬁciency of the lysosomal enzyme glucocerebrosidase
(E.C. 3.2.1.45). Clinically, Gaucher disease can be di-
vided into three types, on the basis of the presence and
rate of progression of neurologic manifestations. Type
1 Gaucher disease, which is the most common form, has
no associated neurologic manifestations. However, pa-
tients with type 1 disease may have a wide spectrum of
clinical presentations and may be asymptomatic or have
a variable age of symptom onset. The most common
ﬁndings in patients with type 1 Gaucher disease are or-
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ganomegaly, cytopenia, and skeletal involvement. Type
2 disease, the rarest form, manifests with severe and
progressive neurologic deterioration and is usually fatal
in utero or within the ﬁrst 2 years of life. Type 3, or
chronic neuronopathic Gaucher disease, generally has
an onset in childhood and, by deﬁnition, includes all
patients with any form of neurologic involvement who
have survived the ﬁrst few years of life.
The gene for human glucocerebrosidase is located on
chromosome 1q21, and there is a highly homologous
pseudogene sequence located 16 kb downstream (Ho-
rowitz et al. 1989; Winﬁeld et al. 1997). In the gluco-
cerebrosidase gene, 1100 different mutations have been
identiﬁed (Grabowski and Horowitz 1997; Beutler and
Gelbart 1998). Although there is a wealth of literature
describing the screening of speciﬁc groups of patients
with Gaucher disease for the presence or absence of
certain common mutations, our understanding of ge-
notype-phenotype correlations remains incomplete.
There is signiﬁcant phenotypic variation, not only
among patients with the same disease type but also
among patients with identical genotypes (Sidransky et
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al. 1994; Grabowski 1997). This is most notable among
homozygotes for the relatively common N370S muta-
tion, since these individuals may have a lifetime without
symptoms (Azuri et al. 1998) or may develop massive
organomegaly or incapacitating skeletal involvement.
Even among patients from a geographic isolate—such
as the Norrbottnian region of Sweden, where type 3
Gaucher disease is seen with increased frequency—a
wide spectrum of presentations are encountered, al-
though all of the patients are homozygous for the point
mutation L444P (Erikson 1986; Dahl et al. 1990). It is
usually even more difﬁcult to predict the phenotype of
compound heterozygotes.
The frequency of speciﬁc mutated alleles varies in
different populations. It has been postulated that foun-
der effects may account for such population differences
(Diaz et al. 1998; Diaz et al. 1999; Lau et al. 1999).
For example, one group has shown that mutations
N370S, L444P, c.84-85insG, and IVS21GrA account
for 196% of the mutated alleles in Ashkenazi Jewish
patients, although they constitute !75% of the mutated
alleles in non-Jews (Beutler et al. 1992; Beutler and Gel-
bart 1993). Among Japanese patients with Gaucher dis-
ease, neither mutation N370S nor c.84-85insG are seen,
but L444P and F213I are relatively common, lending
further support to the founder-effect theory (Kawame
et al. 1993; Eto and Ida 1999). In the Portuguese
Gaucher population, the N370S mutation accounts for
63% of the mutated alleles, and two other rare muta-
tions, G377S and N396T, are commonly encountered
(Amaral et al. 1993; Amaral et al. 1999). The evaluation
of individuals homozygous for the mutations that are
common in different ethnic groups provides a clearer
picture of genotype-phenotype relationships in Gaucher
disease. Recently, more comprehensive mutation proﬁle
studies have been undertaken in two smaller patient
populations in Europe (Germain et al. 1998; Hodanova
et al. 1999).
A limitation of most genotype-phenotype studies pub-
lished in the literature is that they relied solely on PCR-
based mutation-detection techniques to screen for the
presence or absence of speciﬁc mutations. This ap-
proach has inherent problems, because a complex allele
with more than one mutation, a deleted allele, or a
mutation located at a primer site would go undetected.
In addition, recombinant alleles resulting from cross-
over or gene-conversion events between the glucocere-
brosidase gene and its pseudogene—including fusions,
duplications, or deletions—would not be identiﬁed. An
allele carrying a portion of the pseudogene sequencewill
not be ampliﬁed by primers designed to be speciﬁc for
the glucocerebrosidase gene, and the patient may mis-
takenly be designated as a homozygote for the second
allele (Tayebi et al. 1996b). Other strategies are nec-
essary to more accurately genotype patients with
Gaucher disease.
In this study, we performed genotypic analyses on
samples from 152 patients with Gaucher disease, (128
with type 1 disease and 24 with type 3 disease) using
complete-gene sequencing (Tayebi et al. 1998; Stone et
al. 2000), long-template PCR (Tayebi et al. 1996b), re-
striction-site mutation detection (Sidransky et al. 1994),
and the ampliﬁcation refraction mutation system
(ARMS) (Mistry et al. 1992). The allelic frequencies of
speciﬁc mutations in these patients were compared with
respect to ethnic background. The 128 patients with
type 1 Gaucher disease included individuals of Ashke-
nazi ( ) and non-Ashkenazi ( ) origin. Wen = 64 n = 64
also used the same strategy to establish the genotypes
of 24 non-Jewish patients with type 3 Gaucher disease.
Many rare or novel mutations and recombinant alleles
were detected. Since 197% of the total mutant alleles
were identiﬁed, this work represents a comprehensive
analysis of the mutations encountered in our patient
population. However, the study also demonstrates that
even when the majority of DNA mutations are known,
phenotypic differences among patients cannot be fully
accounted for by genotype alone, and that modiﬁer
genes or environmental factors must also be considered.
Material and Methods
High-molecular-weight DNA was isolated from white
blood cells or from cultured ﬁbroblast or lymphoblast
cell lines from affected individuals. A single probandwas
evaluated in each family. A majority of the patients were
seen under an NIMH Institute Review Board–approved
protocol at the Clinical Center at the National Institutes
of Health, and informed consent was obtained. Sixty of
these patients were included in a previous study screen-
ing for the presence of ﬁve speciﬁc mutations (Sidransky
et al. 1994). Ten probands with type 1 disease were
evaluated at the RabinMedical Center in Israel andwere
referred because they were known to have at least one
rare Gaucher allele, on the basis of preliminarymutation
screening in Israel.
In most of the cases, patient DNA was ﬁrst screened
for the common N370S, L444P, R463C, c.84-85insG,
IVS21GrA, and c.1263-1317del mutations, as de-
scribed elsewhere (Tayebi et al. 1996a; Tayebi et al.
1998). The presence of these mutations was then con-
ﬁrmed by sequencing. If mutation L444P was detected,
or if no common mutant alleles were identiﬁed, South-
ern blot analyses using the restriction enzymes SspI and
SstII and long-template PCR ampliﬁcation of the entire
glucocerebrosidase gene were performed to look for
large deletions, recombinations, or duplications (Tayebi
et al. 1996b; Tayebi et al. 1998). Then, the exonic se-
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Figure 1 The distribution of ﬁve mutant alleles among patients
with type 1 Gaucher disease. A, Ashkenazi Jewish patients (108 al-
leles). B, Non-Jewish patients (128 alleles).
quences and most intronic sequences were ampliﬁed in
three fragments of 1.7–3 kb in length, by use of primers
designed to amplify selectively the glucocerebrosidase
gene and not the pseudogene sequence. A fragment en-
compassing exons 1–5 was ampliﬁed by means of the
forward primer 5′-CCTAAAGTTGTCACCCATAC-3′
and the reverse primer 5′-AGCAGACCTACCCTA-
CAGTTT-3′ (annealing temperature 57C, extension
time 3 min). A second fragment covering exons 5–7 was
ampliﬁed by use of the forward primer 5′-GACCT-
CAAATGATATACCTG-3′ and the reverse primer 5′-
AGTTTGGGAGCCAGTCATTT-3′ (annealing temper-
ature 58.5C, extension time 2 min). Lastly, a fragment
extending across exons 8–11 was ampliﬁed by means
of the forward primer 5′-TGTGTGCAAGGTCCAG-
GATCAG-3′ and the reverse primer 5′-ACCACCTA-
GAGGGGAAAGTG-3′ (annealing temperature 61C,
extension time 1 min 30 s). These ampliﬁed segments
were puriﬁed by use of either a GeneClean II kit (Bio
101) or a QIAquick PCR Puriﬁcation Kit (Qiagen) be-
fore sequencing or restriction digests was performed.
Cycle sequencing was accomplished by use of the Dye
Terminator Cycle Sequencing kit (Applied Biosystems),
and all identiﬁed mutations were conﬁrmed by sequenc-
ing with both forward and reverse primers, as described
elsewhere (Stone et al. 2000).
Results
The patient DNA was initially screened for the presence
or absence of four commonly encountered mutations,
IVS21 GrA, c.84-85insG, N370S, and L444P. Figure
1 summarizes the results of this screening and shows the
allelic distribution among the patients with type 1
Gaucher disease in our series. The 10 patients from Israel
were excluded because of the sampling bias. The distri-
bution of the four mutant alleles differed between the
Ashkenazi and non-Jewish populations. Among the Ash-
kenazi patients studied, screening for these four muta-
tions successfully identiﬁed 93% of the mutant alleles.
However, when screening for the four common muta-
tions in the non-Jewish patients, only mutations N370S
and L444P were detected, accounting for 80 (62%) of
128 mutant alleles. PCR screening detected L444P in 36
of the non-Ashkenazi patients. Subsequent sequencing
and Southern blotting demonstrated that 17 patients ac-
tually had L444P as part of a recombinant allele carrying
additional pseudogene sequence alterations (ﬁg. 2) and
that 19 patients had mutation L444P as a single point
mutation. Thus PCR screening for individual mutations
correctly identiﬁed only 63 (49%) of 128 mutant alleles
in the non-Jewish patients.
The speciﬁc genotypes identiﬁed in patients with type
1 Gaucher disease are listed in tables 1 and 2. Most
(97%) of the mutant alleles were identiﬁed. In some of
the cases where one allele remained unknown, complete
sequencing could not be performed, because of limita-
tions in the quantity of available DNA. There were con-
sistent differences between the Ashkenazi Jewish and
non-Jewish patients. All of the N370S homozygotes
identiﬁed were Ashkenazi Jews. Recombinant alleles,
which were not found in any of the Ashkenazi patients,
were found in 30% of the non-Jewish patients studied.
Among the 19 patients identiﬁed with recombinant al-
leles, ﬁve different sites of crossover between the glu-
cocerebrosidase gene and pseudogene were found (ﬁg.
2) (Tayebi et al. 1999b). All ﬁve were located between
intron 8 and exon 10, a region in which the gene and
the pseudogene share high sequence homology (Horo-
witz et al. 1989). Mutation R463C was identiﬁed in 9
(14%) of the non-Jewish patients, but in only 1 Ash-
kenazi Jewish patient. Genotype R463C/G202Rwas en-
countered in three unrelated, non-Jewish probands.
Eleven different genotypes were detected in our 24
patients with type 3 Gaucher disease (table 3). Of the
commonly screened mutations, mutation N370S was
not detected in this group. Two patients had a single
allele with mutation c.84-85insG, and two carried
IVS21GrA. Genotype L444P/L444P was identiﬁed in
ten patients, but there were no L444P heterozygotes.
Six patients were heterozygous for a recombinant allele,
and three different sites of crossovers were noted (ﬁg.
2), all in the same region as those identiﬁed in patients
with type 1 Gaucher disease. No patients were homo-
zygous for a recombinant allele. Mutation R463C was
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Table 1
Genotypes Encountered in American and
Israeli Ashkenazi Jewish Patients with
Type 1 Gaucher Disease
Genotype No. of Patients
American patients:
N370S/N370S 26
N370S/L444P 2
N370S/IVS21GrA 4
N370S/c.84-85insG 15
N370S/V394L 1
N370S/F213I 1
N370S/R463C 1
N370S/Y135X 1
L444P/V394L 1
IVS21GrA/R496H 1
R48W/R120W 1
Israeli patients:
N370S/V394L 4
N370S/R120W 1
N370S/c.1122-
1123insTG
1
N370S/R120Q 1
N370S/W184R 1
N370S/R285C 1
N370S/? 1
Figure 2 Distribution of the identiﬁed sites of crossover between the glucocerebrosidase gene and pseudogene in patients with type 1 and
type 3 Gaucher disease. A total of 19 recombinant alleles were detected in patients with type 1 Gaucher disease and 6 in patients with type 3
Gaucher disease. The horizontal lines connecting the diamond symbols represent the general regions where the crossover must have occurred,
n= the number of recombinant alleles identiﬁed within the region shown. The approximate sites are as follows: RecA, (not shown - identiﬁed
in a patient with type 2 Gaucher disease (Stone et al. 2000) intron 3; RecB, intron 8 or the beginning of exon 9 (before the 55 bp deletion
c.1263-1317 del); RecC, exon 9; RecD, end of exon 9 or beginning of intron 9; RecE, intron 9; RecF, end of intron 9 or beginning of exon
10.
also prevalent among patients with type 3 Gaucher dis-
ease and was found in ten patients.
Discussion
By using restriction-site mutation detection, ARMS,
long-template PCR, Southern blotting, and complete
gene sequencing, we have identiﬁed 97% of the 304
mutant alleles present in the 152 patients in this study.
The identiﬁed mutations included point mutations,
frameshift mutations, recombinant alleles, deletions,
splice mutations, and insertions. In the 64 Ashkenazi
patients with type 1 Gaucher disease, 16 different mu-
tant alleles were identiﬁed, and 32 were identiﬁed in the
64 non-Jewish type 1 patients. In the 24 patients with
type 3 Gaucher disease, 13 distinct mutant alleles were
detected.
Among the patients with type 1 Gaucher disease, our
results roughly support the previously described allele
distributions for Ashkenazi and non-Ashkenazi patient
populations (Grabowski 1997). Screening for four com-
mon Gaucher mutations by PCR-based techniques
would identify 93% of the alleles of the American Ash-
kenazi Jewish subjects. In the non-Jewish population,
only 49% of the alleles would have been identiﬁed cor-
rectly, and, by this screening method, 17 individuals
with recombinant alleles would have been misclassiﬁed
as having only point mutation L444P. The patients with
type 1 Gaucher disease that we studied had a higher
percentage of rare mutations than those in previously
published American studies (Grabowski 1997; Beutler
and Gelbart 1998). This may be attributed to the sam-
pling bias inherent in studying samples at a tertiary
referral center, since we often receive referrals of patients
with mutations that were not detected by standard clin-
ical laboratory testing. This was true of the samples
from Israel, which were sent to us because the patients
were known to have at least one rare allele (table 1).
We continue to caution that there are basic limitations
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Table 2
Genotypes Encountered in Non-Jewish
Patients with Type 1 Gaucher Disease
Genotypea Frequency
N370S/L444P 11
N370S/RecB 1
N370S/RecC 1
N370S/RecD 6
N370S/RecE 1
N370S/RecF 3
L444P/D409H 1
L444P/A90T 1
R463C/R285C 1
N370S/T369M 1
R463C/R257Q 1
N370S/R463C 2
L444P/R170C 1
R463C/G202R 3
RecD/R463C 1
R170P/R170P 1
L444P/R48W 1
N370S/S196P 1
K79N/? 1
N370S/G377S 1
N370S/R131L 1
R257Q/F216Y 1
N370S/D399Y 1
RecD/c.222-224delTAC 1
N370S/R257Q 1
N370S/c.1263-1317del(RecB) 2
RecD/V352L 1
RecF/N117D 1
N370S/c.203delC 2
L444P/A341T 1
N370S/R120W 1
RecD/c.153-154insTACAGC 1
N370S/E326Kc.203-204insC 1
N370S/R120Q 1
L444P/R463C 1
N370S/T134I 1
L444P/L444P 1
N370S/? 5
a RecB–RecF refer to recombinant alleles
with the site of crossover as indicated in ﬁg-
ure 2. Table 3
Genotypes Encountered in 24 Patients
with Type 3 Gaucher Disease
Genotypea No. of Patients
L444P/L444P 10
RecD/R463C 3
c.84-85insG/R463C 2
IVS21GrA/R463C 2
RecD/D409H 1
A190T/G377S 1
Y304X/R463C 1
RecF/N188S 1
D399N/R463C 1
c.1263-1317del(RecB)/? 1
R463C/A176D 1
a RecB–F refer to recombinant alleles
with the site of crossover as shown in ﬁgure
2.
in our ability to predict the severity of a point mutation
on the basis of the associated patient phenotype. It is
clear from many inherited disorders that monogenic
traits are not necessarily simple (Scriver and Waters
1999). Modiﬁer genes, contiguous genes, transporter
proteins, activator proteins, and environmental factors
may contribute signiﬁcantly to phenotype, as has been
demonstrated in other genetic disorders. For example,
in cystic ﬁbrosis, the expression at a modiﬁer locus helps
to deﬁne whether a patient with cystic ﬁbrosis will de-
velop the pancreatic insufﬁcient form of the disease (Es-
tivill 1996). Patients with Hunter syndrome with atyp-
ical phenotypes have been shown to have deletions
encompassing contiguous genes (Timms et al. 1997). In
phenylketonuria, both cis alleles and trans-acting fac-
tors contribute to phenotype (Scriver andWaters 1999).
In a-1-antitrypsin deﬁciency, both environmental fac-
tors—such as smoke—and molecular factors—such as
chaperones and proteases—play a role (Perlmutter
1998). Nonetheless, our extensive genotyping data was
evaluated to determine whether certain genotype-phe-
notype generalizations were possible, especially regard-
ing the newly described mutant alleles.
In our study, 14 novel mutations were detected, 12
of which were identiﬁed in patients with type 1 Gaucher
disease (table 4). Three of these, Y135X, W184R, and
c.1122-1123insTG, were found in Ashkenazi Jewish pa-
tients. In all three, the second allele was N370S. Since
the N370S mutant allele appears to express enough en-
zyme to “protect” against neuronopathic Gaucher dis-
ease, our study did not enable speculation about the
severity of these mutations.
Nine novel mutations were identiﬁed among the non-
Jewish patients with type 1 Gaucher disease (table 4).
Five of the mutations—A90T, N117D, R170C, c.222-
224delTAC (which deletes a downstream threonine)
and c.153-154insTACAGC (which results in a dupli-
cation of the amino acids tyrosine and serine)—were
detected in black patients, and the clinical cases will be
discussed elsewhere (unpublished data). All ﬁve of these
were encountered with more-severe mutations, either a
recombinant allele or mutation L444P, on the second
allele, and thus we suspect that they are relatively mild
mutations. The other four new mutant alleles were each
accompanied by an allele with N370S. Two novel point
mutations, A341T and D399Y, were encountered in pa-
tients with Swedish ancestry, and a third mutation,
T134I, was identiﬁed in an American patient. A fourth
patient carried a novel insertion mutation, c.203-
204insC (introducing a stop codon at a position 34
nucleotides downstream in exon 3), together with a pos-
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Table 4
Rare Mutations Encountered in Patients With Type 1 Gaucher Disease
MUTATION TYPE
MUTATIONS IN
Ashkenazi Patients Non-Jewish Patients
Novel Y135X A90T
W184R N117D
c.1122-1123insTG T134I
R170C
A341T
D399Y
c.222-224delTAC
c.203-204insC
c.153-154insTACAGC
Also reported in type 2 patients R120W R120W
F213I R131L
S196P
G202R
R257Q
D409H
c.1263-1317del
Known as “mild” R48W R48W
R496H K79N
F216Y
V352L
G377S
Previously published (severity unknown) R120Q R120Q
R285C R285C
R463C T369M
V394L R463C
c.203delC
sible polymorphism, E326K (Grace et al. 1999), on the
same allele.
Of the 21 other rare alleles encountered in our pa-
tients with type 1 Gaucher disease (table 4), eight
(R120W, R131L, F213I, S196P, G202R, R257Q,
D409H, and c.1263-1317del) have been previously re-
ported in patients with type 2 Gaucher disease (Stone
et al. 2000) and thus are more likely to be severe. Six
others (R48W, K79N, F216Y, V352L, G377S, and
R496H) have been previously reported as mild (Beutler
and Gelbart 1998). In our patients, mutations R48W,
V352L, and R496H were encountered in patients who
also had the more severe mutations L444P, R120W,
R257Q, or IVS21 GrA, all four of which are de-
scribed in patients with type 2 Gaucher disease, thus
conﬁrming that the former three mutations are likely to
be mild. The severity of the ﬁve other previously de-
scribed rare alleles—R120Q, R285C, T369M, V394L,
and R463C—cannot be established from our data. The
frameshift mutation c.203delC (introducing a stop co-
don 58 bp downstream in exon 3), presumably a null
mutation, was encountered in two unrelated probands
together with N370S.
A total of 19 patients with type 1 Gaucher disease
were found to have recombinant alleles. Five different
sites of crossover were identiﬁed, as illustrated in ﬁgure
2. In two patients, the recombinant allele was exclu-
sively a 55-bp deletion in exon 9, c.1263-
1317del(RecB), presumably resulting from gene con-
version, whereas, in the other 17 patients, larger regions
of pseudogene sequence that included point mutation
L444P were incorporated, as detected by Southern blot
analyses and sequencing. The terms RecArF (tables 2
and 3) (ﬁg. 2) refer to the approximate site of crossover,
but it should be noted that alleles incorporating differ-
ent-sized segments of pseudogene sequence can share
the same crossover site. For example, a crossover at site
RecB resulted in mutation c.1263-1317del in two pa-
tients, whereas, in a third patient, a crossover at this
site resulted in a recombinant allele that included
c.1263-1317del, together with mutations D409H and
L444P and other pseudogene sequence. Several of the
recombinant alleles carried a fusion between the gene
and pseudogene, and others resulted from gene con-
version. Since homozygosity for a recombinant allele
results in early lethality (Tayebi et al. 1999a; Stone et
al. 2000), the second allele encountered in each of the
19 individuals with recombinant alleles is, presumably,
less severe.
Our results have direct implications for laboratories
screening for mutations in patients with type 1 Gaucher
disease. For example, mutation V394L was found in
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9% of the Ashkenazi Jewish patients studied. When
screening this patient population, adding mutation
V394L to the panel could improve the sensitivity of the
screening. For non-Jewish patients, the strategy used to
identify mutant alleles could be altered to detect mu-
tations more commonly seen in this population. Spe-
ciﬁcally, we did not detect mutation IVS21GrA or
c.84-85insG in our series of non-Jewish type 1 patients,
although we have identiﬁed these mutations in non-
Jewish patients with type 2 and type 3 Gaucher disease
(Stone et al. 2000). Mutations R463C, G202R, and
recombinant alleles were found more frequently in non-
Jewish subjects as compared to Ashkenazi patients. We
strongly advocate that DNA from all patients identiﬁed
with mutation L444P be further evaluated by direct
sequencing and Southern blotting to establish the pres-
ence or absence of a recombinant allele or a duplicated
or fusion allele.
The genotyping results of the patients with type 3
Gaucher disease also have relevance for genetic coun-
seling. In this group, it was particularly striking that
clinically similar patients had many different genotypes.
None of the patients were found to have mutation
N370S, conﬁrming that the presence of N370S is pre-
dictive of nonneuronopathic disease. A signiﬁcant pro-
portion of the patients (41%)were L444P homozygotes.
However, all ﬁve of the patients who appeared hetero-
zygous for L444P actually had a recombinant allele,
and, among these ﬁve patients, two different sites of
crossover between the gene and pseudogene (RecD and
RecF) were identiﬁed. An additional patient carried the
55-bp deletion c.1263-1317del(RecB). Mutation
R463C, which was present in 10 (41%) of the patients,
was the second-most-common allele among patients
with type 3 Gaucher disease. Two novel mutations,
A190T (a point mutation) and Y304X (which results
from a 1-bp deletion in exon 8), were encountered in
our patients, each with mutation R463C on the second
allele. Five rare alleles—A176D, G377S, N188S,
D399N, and D409H—were also detected. Two of these,
N188S and G377S, have previously been described in
patients with type 1 Gaucher disease andwere presumed
to be mild (Laubscher et al. 1994; Kim et al. 1996; Choy
et al. 1999).
We have recently completed the genotypic analysis of
31 patients with type 2 Gaucher disease, and all 62
mutant alleles were successfully identiﬁed (Tayebi et al.
1999a; Stone et al. 2000). Homozygosity for a recom-
binant allele results in perinatal lethal type 2 Gaucher
disease, and it appears that most recombinant alleles
are null alleles. Homozygosity for point mutations
S196P, G202R, and H311R also result in type 2
Gaucher disease. Homozygosity for mutation L444P is
usually associated with type 3 Gaucher disease, most
often in patients with compromised horizontal saccadic
eye movements. However, there are a few published
exceptions to this general observation. In our series and
that of others, there have been young patients with this
genotype who have no apparent neurologic involvement
(Kawame et al. 1993; Cox and Schoﬁeld 1997). The
patient which we have included is only four years old,
but her affected younger brother does appear to have
early involvement of his extraocular movements. Long-
term followup of these patients is necessary, as many
of these children later developed neurologic symptoms
(Ida et al. 1999). We did not ﬁnd any true L444P ho-
mozygotes in our series of 31 patients with type 2
Gaucher disease (Stone et al., in press), and believe that
many of the patients with type 2 disease described in
the literature as having genotype L444P/L444P may ac-
tually have at least one recombinant allele.
Homozygosity for mutation N370S is always asso-
ciated with type 1 Gaucher disease, and heterozygosity
for N370S is also predictive of type 1 disease. By use
of the generalizations made from patients with other
homozygous genotypes, correlations can be attempted
in those with heterozygous genotypes. All of our pa-
tients with one L444P allele and one recombinant allele
have type 2 Gaucher disease. Likewise, genotypes
L444P/IVS21GrA and L444P/G202R have only been
encountered in type 2 patients. Thus, it appears that
one L444P allele together with a null allele results in
type 2 Gaucher disease, whereas L444P homozygotes
usually have type 3 disease. A recombinant allele was
encountered together with A90T, c.222-224delTAC,
V352L, N117D, or c.153-154insTACAGC in patients
with type 1 Gaucher disease, which would indicate
that these ﬁve mutations are relatively mild. However,
a recombinant allele—together with either mutation
D409H, mutation N188S, or mutation R463C—re-
sulted in type 3 Gaucher disease. Patients described in
the literature with genotype D409H/D409H have a
unique phenotype, with features including aortic in-
volvement, oculomotor involvement, and hydrocephaly
(Abrahamov et al. 1995; Uyama et al. 1997). Our pa-
tient with a recombinant allele and mutation D409H
shared these unusual features (Stone et al., in press).
However, mutation N188S, seen in a type 3 patient,
had been previously described primarily in Asian pa-
tients with relatively mild disease and was even sug-
gested to be protective from neuronopathic disease (Kim
et al. 1996; Choy et al. 1999).
It is particularly difﬁcult to understand the pheno-
typic consequence of mutation R463C. In the literature,
genotype R463C/R463C was described in an adult pa-
tient with type 1 Gaucher disease (Hatton et al. 1997)
and in a Turkish patient with type 3 disease (Gurakan
et al. 1999). In our series, all patients with R463C/
N370S have had type 1 disease. However, we have had
patients with R463C/R257Q, R463C/R285C, R463C/
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Figure 3 Factors which may contribute to phenotype in patients
with Gaucher disease.
G202R, R463C/RecD, and R463C/L444P with type 1
Gaucher disease and patients with R463C/RecD,
R463C/IVS21GrA, R463C/c.84-85insG and R463C/
A176D with type 3 Gaucher disease. Since G202R,
R257Q, IVS21GrA, c.84-85insG, and recombinant
alleles are all severe or null mutations found in patients
with type 2 Gaucher disease, these relationships are
inconsistent.
Several of the mutations discussed here have been
expressed previously in different in vitro–expression
systems (Ohashi et al. 1991; Choy et al. 1996; Grace
et al. 1997, 1999; Pasmanik-Chor et al. 1997). Al-
though, in all these studies, the enzymatic activity of
expressed enzyme with mutation N370S was higher
than with mutation L444P, it is very difﬁcult to compare
the enzyme activity associated with mutant alleles
among different studies, as these studies use different
preparation and assay systems.
Our study demonstrates that by employing several
different mutation-detection strategies, including direct
sequencing, 97% of the mutant alleles could be iden-
tiﬁed in our large population of patients with Gaucher
disease. Fourteen novel mutations are also described.
We speciﬁcally searched for recombinant alleles, and we
found them in 15% of the patients with type 1 and
25% of the patients with type 3 Gaucher disease. This
study not only identiﬁes a large number of novel and
rare mutations in patients with types 1 and 3 Gaucher
disease but accurately assesses the prevalence of recom-
binant alleles. These two features enhance our ability
to attempt genotype-phenotype correlations. Although
relevant generalizations can be made, our data suggest
that additional factors must contribute to the range of
phenotypes encountered in patients with Gaucher dis-
ease (ﬁg. 3). Clearly, the identiﬁcation of speciﬁc point
mutations is useful, but whether these mutations are
part of a complex or recombinant allele is important.
Also, since the region on chromosome 1q21 encom-
passing human glucocerebrosidase is particularly gene
rich, with seven genes and two pseudogenes within an
∼75-kb region (Winﬁeld et al. 1997), the possible con-
tribution of genes contiguous to glucocerebrosidase in
certain patients is particularly intriguing. Another factor
which could contribute to phenotype is the involvement
of an alternate substrate. Glucosylsphingosine, a lipid
which is also degraded by the enzyme glucocerebrosi-
dase, is elevated in tissues from patients with Gaucher
disease, including the brains of patients with neuron-
opathic Gaucher disease (Nilsson and Svennerholm
1982; Orvisky et al. 1999). The rate of accumulation
and degradation of glucosylsphingosine or the amount
stored may be responsible for certain disease manifes-
tations in patients.
As now seen in many Mendelian disorders, other
genes may also contribute to the range of symptoms
encountered. In patients with Gaucher disease, two re-
lated genes are those encoding for sphingolipid activator
proteins (SAPs) and lysosome-associated membrane
proteins (LAMPs). The SAPs are small nonenzymatic
glycoproteins that are necessary for the degradation of
lysosomal sphingolipids (Morimoto et al. 1990). SAP-
C is essential for the degradation of glucocerebroside
and patients with mutations in the gene encoding SAP-
C demonstrate glucocerebroside storage with hepatos-
plenomegaly and Gaucher cells in the bone marrow,
along with oculomotor and neurologic abnormalities
(Pampols et al. 1999). It has recently been shown that
the lysosome-associated membrane proteins, LAMP-1
and LAMP-2, may participate in the intracellular deliv-
ery of glucocerebrosidase from the endoplasmic retic-
ulum to lysosomes, and that this transport may be de-
fective in patients with Gaucher disease (Zimmer et al.
1999). It is likely that other modiﬁer genes will also be
identiﬁed.
Lastly, environmental factors clearly contribute to the
heterogeneity observed in patients with Gaucher disease
(ﬁg. 3). It has been shown that, in Gaucher disease,
siblings with identical genotypes may have different
clinical manifestations, different disease complications,
and even different responses to therapy (Cox and Scho-
ﬁeld 1997; Grabowski 2000). Factors such as viral ill-
nesses, surgery, pregnancy, and trauma may precipitate
the development or progression of manifestations in cer-
tain patients.
Therefore, we caution against relying solely on gen-
otypes to predict prognosis or the need for therapy in
patients with Gaucher disease. A better understanding
of the functional consequences of speciﬁc mutations at
the protein level, the possible involvement of genes con-
tiguous to human glucocerebrosidase (Winﬁeld et al.
1997) and the role of activator proteins (Morimoto et
al. 1990), transporter proteins (Zimmer et al. 1999) and
other modiﬁer genes may enhance genotype-phenotype
studies. The generation of mouse models homozygous
for speciﬁc Gaucher mutations may also better clarify
Koprivica et al.: Mutant Alleles in Gaucher Disease 1785
the phenotypic consequences of the observed mutant
alleles.
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